CD274 and hyperthyroidism: Hyperthyroidism showed a predicted incidence ranging from 0.6% (95% CI, 0.2–1.8%) for anti-PD-L1 mAbs to 8.0% (95% CI, 4.1–15.3) for combination regimens.